Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Ocul Immunol Inflamm ; 31(1): 56-64, 2023 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-34686121

RESUMO

PURPOSE: To describe the clinical characteristics and longitudinal pattern of visual acuity (VA) of pediatric patients with uveitis at a tertiary center in Thailand. METHODS: We retrospectively reviewed the records of children with uveitis ≤16 years who presented to the clinic between January 2010 and June 2020. RESULTS: The mean age at onset was 9.1(±4.3) years; the main characteristics were chronic (64.4%), unilateral (68.6%), and panuveitis (39%). The common etiologies were ocular toxoplasmosis (11.9%), herpetic uveitis (10.2%), and ocular toxocariasis (6.8%). Further, 40% of the eyes presented with VA of ≤20/200; mean VA at baseline improved from 0.93 to 0.72 logMAR at 3 months after presentation (P < .001), the baseline VA of ≤20/200 was significantly associated with poor VA outcome at 1 year. CONCLUSION: Chronic, unilateral, and panuveitis represented the majority of our children with uveitis. Infectious etiology was common. Significant VA improvement can be achieved with optimum management.


Assuntos
Pan-Uveíte , Uveíte , Criança , Humanos , Pré-Escolar , Adolescente , Estudos Retrospectivos , Tailândia/epidemiologia , Uveíte/diagnóstico , Uveíte/epidemiologia , Acuidade Visual
3.
Medicine (Baltimore) ; 101(27): e29807, 2022 Jul 08.
Artigo em Inglês | MEDLINE | ID: mdl-35801769

RESUMO

To evaluate the efficacy of intravitreal dexamethasone implants (Ozurdex®) for the treatment of macular edema (ME) associated with retinal vascular diseases in real-life situations. This retrospective study included patients with ME associated with retinal vascular occlusion (RVO) or diabetic macular edema (DME) treated with dexamethasone implants. Demographic data, best-corrected visual acuity (BCVA), and central retinal thickness (CRT) at baseline and at 1, 3, and 6 months postoperatively were collected and analyzed, and the adverse events were recorded. Forty-four eyes, 42 patients were included in the study. The mean logMAR BCVA improved from 0.79 ± 0.38 at baseline to 0.60 ± 0.34 (P < 0.001), 0.72 ± 0.38 (P = .002), and 0.72 ± 0.37 (P = .002) at 1, 3, and 6 months, respectively. The CRT decreased from 526.70 ± 159.58 µm at baseline to 279 ± 66.23, 422.91 ± 206.99, and 350.23 ± 151.51 µm at 1, 3, and 6 months, respectively (P < 0.001, all visits). The average number of injections was 1.43 ± 0.5. Nineteen eyes (43.18%) received second injections at an interval of 4.20 ± 0.61 months. The mean logMAR BCVA was greater in RVO than in DME patients and in treatment-naïve eyes than in previously treated ones. The baseline CRT of the reinjection group was significantly higher than that of the single-injection group for both the RVO (P < 0.001) and DME groups (P = .002). Nine eyes (20.45%) with increasing intraocular pressure (IOP) were well controlled with medication, and cataract progression was observed in five eyes (21.73%) during follow-up. The dexamethasone implant was effective for the treatment of macular edema secondary to RVO and DME in terms of visual acuity and CRT improvement over 6 months. The visual acuity was greater in the RVO and treatment-naïve eyes. Reinjection may be associated with a high baseline CRT. The increase in the occurrence of IOP and cataract progression was similar to that reported in previous studies.


Assuntos
Catarata , Retinopatia Diabética , Edema Macular , Oclusão da Veia Retiniana , Catarata/complicações , Dexametasona/uso terapêutico , Retinopatia Diabética/induzido quimicamente , Retinopatia Diabética/complicações , Retinopatia Diabética/tratamento farmacológico , Implantes de Medicamento , Glucocorticoides/uso terapêutico , Humanos , Injeções Intravítreas , Edema Macular/complicações , Edema Macular/etiologia , Oclusão da Veia Retiniana/complicações , Oclusão da Veia Retiniana/tratamento farmacológico , Estudos Retrospectivos
4.
Acta Ophthalmol ; 96(6): e727-e731, 2018 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-29998553

RESUMO

PURPOSE: To investigate retinal blood flow and oxygen saturation changes in patients diagnosed with retinopathy following plaque radiation treatment to treat choroidal melanoma. METHODS: Eight patients (mean age 55.75 years, SD 12.58 years) who have developed unilateral ischaemic radiation-related retinopathy as confirmed by wide-field fluorescein angiography were recruited for the study. The fellow eye with no other ocular or retinal pathology was used as control. Both eyes underwent measurement of total retinal blood flow (TRBF) and retinal blood oxygen saturation using prototype methodologies of Doppler Spectral Domain Optical Coherence Tomography (OCT) and Hyperspectral Retinal Camera, respectively. RESULTS: The average TRBF in the retinopathy eye was significantly lower compared to the fellow eye (33.48 ± 12.73 µl/min versus 50.37 ± 15.26 µl/min; p = 0.013). The arteriolar oxygen saturation (SaO2 ) and venular oxygen saturation (SvO2 ) were higher in the retinopathy eye compared to the fellow eye (101.11 ± 4.26%, versus 94.45 ± 5.79%; p = 0.008) and (62.96 ± 11.05% versus 51.24 ± 6.88%, p = 0.051), respectively. CONCLUSION: The ionizing radiation seems to have an impact on the TRBF, SaO2 and SvO2 , clinically presenting similar to a rapidly developing diabetic retinopathy. The results show an altered retinal vascular physiology in patients with radiation-related retinopathy.


Assuntos
Angiofluoresceinografia/métodos , Lesões por Radiação/complicações , Fluxo Sanguíneo Regional/fisiologia , Doenças Retinianas/fisiopatologia , Vasos Retinianos/fisiopatologia , Tomografia de Coerência Óptica/métodos , Neoplasias da Coroide/radioterapia , Progressão da Doença , Feminino , Fundo de Olho , Humanos , Melanoma/radioterapia , Pessoa de Meia-Idade , Lesões por Radiação/diagnóstico , Lesões por Radiação/fisiopatologia , Doenças Retinianas/diagnóstico , Doenças Retinianas/etiologia , Vasos Retinianos/diagnóstico por imagem , Vasos Retinianos/efeitos da radiação
5.
Retina ; 38(3): 490-496, 2018 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-28196056

RESUMO

PURPOSE: To analyze the effects of a dexamethasone intravitreal implant (DEX; Ozurdex 700 µg; Allergan) administered immediately after cataract surgery in diabetic patients. METHODS: This prospective, single-arm, open label study (NCT01748487 at ClinicalTrials.gov) involved Type 2 diabetic patients with at least mild diabetic retinopathy (DR) who underwent cataract surgery and DEX insertion after phacoemulsification, and intraocular lens implantation were enrolled. Best-corrected visual acuity and central retinal thickness (CRT) measured by spectral-domain optical coherence tomography were recorded at 1 week preoperatively, and 1 week, 1 month, and 3 months after surgery. Adverse events were also recorded. RESULTS: Twenty-four eyes of 24 patients (17 [70.8%] men; mean age 63.7 ± 8.7 years) with mild nonproliferative DR (41.7%), moderate nonproliferative DR (33.3%), severe nonproliferative DR (16.7%), or treated proliferative DR (8.3%) were selected. After DEX treatment, mean CRT changed from 241.1 µm (95% confidence interval, 227.5-254.6 µm) at baseline to 236.9 µm (95% confidence interval, 223.9-249.9 µm) at 1 week (P = 0.09), 238.9 µm (95% confidence interval, 225.5-252.3 µm) at 1 month (P = 0.44), and 248 µm (95% confidence interval, 232.4-260.8 µm) at 3 months (P = 0.15). No eyes showed a postoperative increase >50 µm in the CRT at any visit. A 10% increase in CRT was found in 8.3% of eyes. Mean best-corrected visual acuity significantly improved from 0.37 (20/50) at baseline to 0.19 (20/30) at 1 week, 0.12 (20/25) at 1 month, and 0.12 (20/25) at 3 months (P < 0.001 for each comparison). Mean intraocular pressure before surgery was 13.8 mmHg, and none of the patients developed an intraocular pressure ≥22 mmHg at any visit. None of the patients developed any serious adverse events during the follow-up. CONCLUSION: These short-term results suggest that a single DEX injection intraoperatively after phacoemulsification could avoid an increase in CRT after cataract surgery in diabetic patients.


Assuntos
Anti-Inflamatórios/administração & dosagem , Dexametasona/administração & dosagem , Retinopatia Diabética/tratamento farmacológico , Edema Macular/prevenção & controle , Facoemulsificação/efeitos adversos , Complicações Pós-Operatórias/prevenção & controle , Idoso , Retinopatia Diabética/prevenção & controle , Implantes de Medicamento , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Acuidade Visual
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA